Corneal Microcyst-Like Epithelial Changes Associated To Recently Approved Belantamab Mafodotin Therapy

Published 2022 - 40th Congress of the ESCRS

Reference: PO342 | Type: ESCRS 2022 - Posters | DOI: 10.82333/r4jk-p511

Authors: Lucia I. Santana Garcia ¹ , MIRIAM GARCIA FERNANDEZ ¹ , MARTA ALVAREZ CORONADO ¹ , BEGOÑA BAAMONDE ARBAIZA ² , LUIS FERNANDEZ VEGA ² , PABLO SOLER BARTRINA ³ , MARIA LUZ GUARDATI* ³

¹UVEITIS DEPARTMENT,HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS,OVIEDO,Spain, ²CORNEA DEPARTMENT,HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS,OVIEDO,Spain, ³CORNEA DEPARTMENT,HOSPITAL EL BIERZO,LEON,Spain

Purpose

To report a case of bilateral corneal microcyst-like epithelial changes associated with belantamab mafodotin therapy after Acute Retinal Necrosis (ARN) due to CMV reactivation.

Setting

Belantamab is a recently FDA-approved treatment for relapsed or refractory multiple myeloma and its side effects are already under surveillance.

Methods

A 70-year-old woman with refractory multiple myeloma developed decreased visual acuity and bilateral corneal microcyst-like peripheral epithelial changes (MECs). The patient is subjected to Belantamab after more than six lines of inefficient treatment against multiple myeloma and having developed an acute retinal necrosis due to CMV in addition.

Results

During the follop-up, treatment against CMV NRA was effective. Cataract surgery was needed to improve visual acuity (VA). Nevertheless, VA was not restored to baseline due to MECs development after treatment. Belantamab dose distancing was necessary to achieve cyst reduction.

Conclusions

Collaboration between ophthalmologists and hematologists is imperative to detect possible side effects and adjust treatment as necessary. Further studies are needed to evaluate the formation of corneal microcyst-like epithelial changes.